Glucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia.
Antidiabetics
dementia
diabetes
hyperglycemia
mortality
propensity-score
Journal
Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863
Informations de publication
Date de publication:
2022
2022
Historique:
pubmed:
18
1
2022
medline:
12
4
2022
entrez:
17
1
2022
Statut:
ppublish
Résumé
The effectiveness of glucose-lowering drugs (GLDs) is unknown among patients with dementia. To analyze all-cause mortality among users of six GLDs in dementia and dementia-free subjects, respectively. This was a longitudinal open-cohort registry-based study using data from the Swedish Dementia Registry, Total Population Register, and four supplemental registers providing data on dementia status, drug usage, confounders, and mortality. The cohort comprised 132,402 subjects with diabetes at baseline, of which 11,401 (8.6%) had dementia and 121,001 (91.4%) were dementia-free. Subsequently, comparable dementia - dementia-free pairs were sampled. Then, as-treated and intention-to-treat exposures to metformin, insulin, sulfonylurea, dipeptidyl-peptidase-4 inhibitors, glucagon-like peptide-1 analogues (GLP-1a), and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) were analyzed in the parallel dementia and dementia-free cohorts. Confounding was addressed using inverse-probability weighting and propensity-score matching, and flexible parametric survival models were used to produce hazard ratios (HR) and 95% confidence intervals (CI) of the association between GLDs and all-cause mortality. In the as-treated models, increased mortality was observed among insulin users with dementia (HR 1.34 [95%CI 1.24-1.45]) as well as in dementia-free subjects (1.54 [1.10-1.55]). Conversely, sulfonylurea was associated with higher mortality only in dementia subjects (1.19 [1.01-1.42]). GLP-1a (0.44 [0.25-0.78]) and SGLT-2i users with dementia (0.43 [0.23-0.80]) experienced lower mortality compared to non-users. Insulin and sulfonylurea carried higher mortality risk among dementia patients, while GLP-1a and SGLT-2i were associated with lower risk. GLD-associated mortality varied between dementia and comparable dementia-free subjects. Further studies are needed to optimize GLD use in dementia patients.
Sections du résumé
BACKGROUND
The effectiveness of glucose-lowering drugs (GLDs) is unknown among patients with dementia.
OBJECTIVE
To analyze all-cause mortality among users of six GLDs in dementia and dementia-free subjects, respectively.
METHODS
This was a longitudinal open-cohort registry-based study using data from the Swedish Dementia Registry, Total Population Register, and four supplemental registers providing data on dementia status, drug usage, confounders, and mortality. The cohort comprised 132,402 subjects with diabetes at baseline, of which 11,401 (8.6%) had dementia and 121,001 (91.4%) were dementia-free. Subsequently, comparable dementia - dementia-free pairs were sampled. Then, as-treated and intention-to-treat exposures to metformin, insulin, sulfonylurea, dipeptidyl-peptidase-4 inhibitors, glucagon-like peptide-1 analogues (GLP-1a), and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) were analyzed in the parallel dementia and dementia-free cohorts. Confounding was addressed using inverse-probability weighting and propensity-score matching, and flexible parametric survival models were used to produce hazard ratios (HR) and 95% confidence intervals (CI) of the association between GLDs and all-cause mortality.
RESULTS
In the as-treated models, increased mortality was observed among insulin users with dementia (HR 1.34 [95%CI 1.24-1.45]) as well as in dementia-free subjects (1.54 [1.10-1.55]). Conversely, sulfonylurea was associated with higher mortality only in dementia subjects (1.19 [1.01-1.42]). GLP-1a (0.44 [0.25-0.78]) and SGLT-2i users with dementia (0.43 [0.23-0.80]) experienced lower mortality compared to non-users.
CONCLUSION
Insulin and sulfonylurea carried higher mortality risk among dementia patients, while GLP-1a and SGLT-2i were associated with lower risk. GLD-associated mortality varied between dementia and comparable dementia-free subjects. Further studies are needed to optimize GLD use in dementia patients.
Identifiants
pubmed: 35034902
pii: JAD215337
doi: 10.3233/JAD-215337
pmc: PMC9028644
doi:
Substances chimiques
Hypoglycemic Agents
0
Insulin
0
Sodium-Glucose Transporter 2 Inhibitors
0
Sulfonylurea Compounds
0
Glucagon-Like Peptide 1
89750-14-1
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
245-257Références
Diabetes Care. 2017 Sep;40(9):1159-1166
pubmed: 28655740
Diabetes Obes Metab. 2015 Apr;17(4):350-62
pubmed: 25399739
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Lancet Diabetes Endocrinol. 2018 Feb;6(2):105-113
pubmed: 29221659
Eur J Epidemiol. 2019 Apr;34(4):423-437
pubmed: 30929112
Stat Med. 2002 Aug 15;21(15):2175-97
pubmed: 12210632
Alzheimers Dement. 2013 Nov;9(6):649-56
pubmed: 23474042
Diabetes Obes Metab. 2017 Jun;19(6):831-841
pubmed: 28116795
Ann Intern Med. 2016 Jun 7;164(11):740-51
pubmed: 27088241
J Alzheimers Dis. 2020;76(4):1581-1594
pubmed: 32741836
Cardiovasc Diabetol. 2019 Aug 28;18(1):112
pubmed: 31462224
JAMA. 2016 Jul 19;316(3):313-24
pubmed: 27434443
J Alzheimers Dis. 2016;51(4):1197-208
pubmed: 26967226
BMJ. 2012 Apr 19;344:e1771
pubmed: 22517929
Diabetes Care. 2018 Jan;41(1):6-10
pubmed: 29263192
Ageing Res Rev. 2017 Nov;40:31-44
pubmed: 28802803
BMJ Open Diabetes Res Care. 2020 Jun;8(1):
pubmed: 32591373
BMC Med. 2014 Oct 31;12:192
pubmed: 25358236
Diabetes Obes Metab. 2010 Jan;12(1):47-53
pubmed: 19788429
BMJ Open Diabetes Res Care. 2020 Jan;8(1):
pubmed: 31958305
PLoS Med. 2016 Apr 12;13(4):e1001992
pubmed: 27071029
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Eur J Epidemiol. 2017 Sep;32(9):765-773
pubmed: 28983736
Lancet. 2017 Dec 16;390(10113):2673-2734
pubmed: 28735855
Lancet Diabetes Endocrinol. 2017 Jan;5(1):43-52
pubmed: 27865756
Diabetologia. 2018 Dec;61(12):2461-2498
pubmed: 30288571
Cardiovasc Diabetol. 2020 Jun 10;19(1):74
pubmed: 32522260
Biochim Biophys Acta. 2015 May;1853(5):1046-59
pubmed: 25667085
Neurology. 2013 May 14;80(20):1888-94
pubmed: 23596063
Diabetes Care. 2020 Jan;43(Suppl 1):S152-S162
pubmed: 31862755
J Geriatr Psychiatry Neurol. 2016 Sep;29(5):261-70
pubmed: 27502301
Epidemiology. 2000 Sep;11(5):550-60
pubmed: 10955408
JAMA. 2009 Apr 15;301(15):1565-72
pubmed: 19366776
Eur J Epidemiol. 2016 Feb;31(2):125-36
pubmed: 26769609
Diabetes Care. 2017 May;40(5):706-714
pubmed: 28428321
PLoS One. 2015 Feb 19;10(2):e0116538
pubmed: 25695768
Diabetes Care. 2012 Apr;35(4):787-93
pubmed: 22374637
BMC Public Health. 2011 Jun 09;11:450
pubmed: 21658213
Lancet Diabetes Endocrinol. 2016 May;4(5):411-9
pubmed: 27009625
Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):726-35
pubmed: 16897791